Developmental Psychopharmacology (R01) | Apply Online

Opportunity Summary:

The Developmental Psychopharmacology (R01) opportunity (Funding Opportunity Number PA-09-111) is a National Institutes of Health (NIH) funding announcement that supports research on how psychotherapeutic and other psychotropic medications affect the developing brain. Its central goal is to move beyond broad statements about pediatric medication safety or efficacy and instead pin down the neurobiological and physiological effects of these drugs across development, with a strong emphasis on identifying the precise developmental profile of response. In practical terms, the FOA is looking for studies that can map how immature neural systems respond at different ages or developmental stages, recognizing that a medication can have different mechanisms, benefits, or risks depending on when in development it is administered. The research scope is intentionally broad: projects can be conducted in human populations, in animal models, or in other relevant model systems, as long as they directly address how exposure to psychotropic agents used to treat childhood mental disorders influences neurobiology in the immature brain.

This FOA uses the NIH Research Project Grant (R01) mechanism, meaning it is designed for full-scale, hypothesis-driven research projects with sufficient preliminary rationale and a clear plan for producing definitive, publishable outcomes. The announcement also notes that it runs in parallel with a companion FOA of the same scientific scope, PA-09-112, which uses the R21 mechanism for exploratory or developmental work. That pairing signals NIH interest in both mature research programs ready for an R01 and earlier-stage, higher-risk ideas that may fit better under an R21, while keeping the scientific focus consistent across both announcements.

From a topic perspective, the announcement is centered on developmental psychopharmacology as it relates to pediatric mental health treatment. The key theme is neurobiological impact: how medications influence brain physiology, circuitry, neurochemistry, and other biological processes during periods of rapid neural maturation. The wording highlights "mapping" and "developmental profile," which points toward research designs that examine age-dependent trajectories or sensitive windows of response. Studies might, for example, compare outcomes following exposure during early childhood versus adolescence, or examine how developmental stage alters pharmacodynamic effects in brain regions relevant to psychiatric symptoms. Because the FOA explicitly welcomes both animal and human studies, it supports a range of approaches, including mechanistic laboratory work that can probe neural pathways in detail, as well as clinically grounded studies that observe medication effects in treated pediatric populations. The overarching aim is to improve understanding of how commonly used psychotropic treatments interact with brain development, information that can ultimately inform safer prescribing, better dosing strategies, and more developmentally appropriate interventions.

Administratively, this is a discretionary grant opportunity under NIH, with activity areas spanning education, health, income security, and social services, reflecting the cross-cutting public health significance of child and adolescent mental health. The FOA is associated with multiple CFDA program areas: 93.242 (Mental Health Research Grants), 93.279 (Drug Abuse and Addiction Research Programs), and 93.865 (Child Health and Human Development Extramural Research). There is no cost-sharing or matching requirement, which is typical for NIH research project grants and reduces barriers for applicants that might not be able to provide non-federal matching funds.

Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants listed include public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses and other for-profit organizations, state and local governments (including counties, cities/townships, special districts), independent school districts, public housing authorities/Indian housing authorities, and tribal governments and tribal organizations. The eligibility details also explicitly include a range of mission- or population-focused institutions and organizational types, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and foreign (non-U.S.) entities. This broad eligibility signals an interest in attracting multidisciplinary teams and diverse research settings, including those with strong connections to pediatric and underserved populations.

In terms of funding, the FOA states that awards depend on the availability of NIH funds and on receiving a sufficient number of meritorious applications. It does not promise a specific number of awards; instead, it reflects standard NIH practice where applications compete based on scientific merit, programmatic priorities, and budget considerations. Key dates in the source data indicate it was posted on February 25, 2009, with closing dates listed in the record (including an original closing date of January 7, 2012, and a current closing date shown as January 7, 2010), and an archive date of February 7, 2010, indicating that the opportunity is no longer active in that particular cycle. For the authoritative, full text of requirements and instructions, the archived NIH Guide page is referenced at http://grants.nih.gov/grants/guide/pa-files/PA-09-111.html, and NIH provides webmaster contacts for access or linking issues through the Office of Extramural Research.

Overall, PA-09-111 is best understood as an NIH call for rigorous R01-level research that clarifies how psychiatric medications interact with brain development, with the intent of producing a more developmentally precise evidence base for pediatric psychopharmacology. The emphasis on neurobiological mechanisms and developmental timing reflects a recognition that children are not simply smaller adults pharmacologically or neurologically, and that treatment decisions in pediatric mental health should be guided by data that accounts for the unique features of the developing nervous system.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health Income Security and Social Services

Next opportunity: ROSES 2009 Space Archaeology

Previous opportunity: Developmental Psychopharmacology (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 111

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 111) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 111", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.